Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers.

Details

Ressource 1Download: 39039441.pdf (1180.69 [Ko])
State: Public
Version: Final published version
License: CC BY 4.0
Serval ID
serval:BIB_9D8A4D752094
Type
Article: article from journal or magazin.
Publication sub-type
Case report (case report): feedback on an observation with a short commentary.
Collection
Publications
Institution
Title
Primary diffuse large B-cell lymphoma of the central nervous system identified with CSF biomarkers.
Journal
BMC neurology
Author(s)
Loser V., Segot A., de Leval L., Bisig B., Brouland J.P., Hewer E., Barcena C., Hottinger A.F., Pot C.
ISSN
1471-2377 (Electronic)
ISSN-L
1471-2377
Publication state
Published
Issued date
22/07/2024
Peer-reviewed
Oui
Volume
24
Number
1
Pages
250
Language
english
Notes
Publication types: Case Reports ; Journal Article
Publication Status: epublish
Abstract
Diagnosis of primary diffuse large B-cell lymphoma of the central nervous system (PCNSL) is challenging and often delayed. MRI imaging, CSF cytology and flow cytometry have a low sensitivity and even brain biopsies can be misleading. We report three cases of PCNSL with various clinical presentation and radiological findings where the diagnosis was suggested by novel CSF biomarkers and subsequently confirmed by brain biopsy or autopsy.
The first case is a 79-year-old man with severe neurocognitive dysfunction and static ataxia evolving over 5 months. Brain MRI revealed a nodular ventriculitis. An open brain biopsy was inconclusive. The second case is a 60-year-old woman with progressive sensory symptoms in all four limbs, evolving over 1 year. Brain and spinal MRI revealed asymmetric T2 hyperintensities of the corpus callosum, corona radiata and corticospinal tracts. The third case is a 72-year-old man recently diagnosed with primary vitreoretinal lymphoma of the right eye. A follow-up brain MRI performed 4 months after symptom onset revealed a T2 hyperintense fronto-sagittal lesion, with gadolinium uptake and perilesional edema. In all three cases, CSF flow cytometry and cytology were negative. Mutation analysis on the CSF (either by digital PCR or by next generation sequencing) identified the MYD88 L265P hotspot mutation in all three cases. A B-cell clonality study, performed in case 1 and 2, identified a monoclonal rearrangement of the immunoglobulin light chain lambda (IGL) and kappa (IGK) gene. CSF CXCL-13 and IL-10 levels were high in all three cases, and IL-10/IL-6 ratio was high in two. Diagnosis of PCNSL was later confirmed by autopsy in case 1, and by brain biopsy in case 2 and 3.
Taken together, 5 CSF biomarkers (IL-10, IL-10/IL-6 ratio, CXCL13, MYD88 mutation and monoclonal IG gene rearrangements) were strongly indicative of a PCNSL. Using innovative CSF biomarkers can be sensitive and complementary to traditional CSF analysis and brain biopsy in the diagnosis of PCNSL, potentially allowing for earlier diagnosis and treatment.
Keywords
Humans, Male, Aged, Lymphoma, Large B-Cell, Diffuse/cerebrospinal fluid, Lymphoma, Large B-Cell, Diffuse/diagnosis, Middle Aged, Female, Central Nervous System Neoplasms/cerebrospinal fluid, Central Nervous System Neoplasms/diagnostic imaging, Central Nervous System Neoplasms/diagnosis, Central Nervous System Neoplasms/pathology, Biomarkers, Tumor/cerebrospinal fluid, Brain/pathology, Brain/diagnostic imaging, Magnetic Resonance Imaging, Biomarker, Cerebrospinal fluid, Lymphoma, PCNSL
Pubmed
Open Access
Yes
Create date
23/07/2024 15:22
Last modification date
24/07/2024 7:14
Usage data